NCT02509598 2024-06-28
A Study of Lymphoseek® as a Lymphoid Tissue Targeting Agent in Pediatric Patients With Melanoma, Rhabdomyosarcoma, or Other Solid Tumors Who Are Undergoing Lymph Node Mapping
Cardinal Health 414, LLC
Phase 2 Completed
Clinical Trials
6 trialsNCT04511026 2023-10-11
Concurrent Use Lymphoseek & Indocyanine Green in Sentinel Lymph Node Detection in Endometrial Cancer
Stanford University
Phase 2 Terminated
NCT03405142 2022-11-10
Panitumumab-IRDye800 Compared to Sentinel Node Biopsy and (Selective) Neck Dissection in Identifying Metastatic Lymph Nodes in Patients With Head&Neck Cancer
Stanford University
Phase 2 Completed
NCT01902953 2021-06-23
Lymphoseek® as Lymphoid Tissue Targeting Agents in Colon Cancer(CNC)
Maimonides Medical Center
Phase 2 Completed
NCT02509585 2019-02-11
A Trial of Comparing the Pathology Status of Lymphoseek®-Identified Sentinel Lymph Nodes Relative to the Pathological Pathology Status of Nonsentinel Lymph Nodes in Nodal Staging of Subjects With Known Cancer of the Cervix Who Are Undergoing Lymph Node Dissection
Cardinal Health 414, LLC
Phase 2 Terminated
NCT02201420 2016-09-27
Evaluation of Tc 99m Tilmanocept Localization in Primary Cutaneous Kaposi's Sarcoma and Lymphatic Drainage by SPECT/CT
Navidea Biopharmaceuticals
Phase 2 Completed